The European Commission has given Zuranolone Traffic Authorization for the treatment of postpartum depression.
It is a perinatal disorder, a mental illness that can affect women after childbirth and is characterized by persistent sadness, anxiety, fatigue and difficulty in functionality. It can be severe and long -term, with negative consequences for the mother and child, and to date there has been no appropriate treatment for this condition, with antidepressants already in circulation not to act in a short time.
The marketing authorization is based on the positive scientific evaluation of the European Medicines Agency (EMA). According to this evaluation, the benefit of Zoranolone lies in its ability to reduce the depressive symptoms associated with postpartum depression in a fairly short period of time, that is, after two weeks of treatment. Zoranolone is prescribed and may have some side effects on the packaging.
It is noted that the substance should not be used during pregnancy and it is not recommended to use it during breastfeeding.
